CYP19A1 and breast carcinoma: In addition, his 2012 article was the most cited paper, with a total of 2,018 citations, which demonstrated that treatment with the mTOR inhibitor everolimus in combination with an aromatase inhibitor will improve progression-free survival in patients with hormone receptor-positive advanced breast cancer who received prior treatment with a nonsteroidal aromatase inhibitor (11).